2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1610

The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
Abstract Number: 1341

The Impact of Anti-Cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Patients with RA of Varying Disease Duration
Abstract Number: 2048

the Impact of Diagnostic Misregistration of Rheumatoid Arthritis on the Establishment of a Value Based Healthcare System
Abstract Number: 1619

The Impact of Disease Characteristics on Habitual Physical Activity and Sedentary Behavior Among Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 198

The Impact of Electronic Consults (E-Consults) on Positive ANA Referrals in a Veteran Population
Abstract Number: 2302

The Impact of JIA on Physician and Patient-Reported Outcomes over the First Five Years Following Diagnosis
Abstract Number: 230

The Impact of Limited Health Literacy on Patient-Reported Outcomes (PROs) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2810

The Impact of Psychiatric Comorbidity on Health Care Utilization for Youth with Systemic Lupus Erythematosus
Abstract Number: 348

The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome
Abstract Number: 828

The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates
Abstract Number: 416

The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX
Abstract Number: 1135

the Incidence of Knee Chondrocalcinosis and Its Risk Factors in Community-Based Cohort
Abstract Number: 822

The Incidence Rate of Deep Vein Thrombosis and/or Pulmonary Embolism in Patients with Giant Cell Arteritis – Single Center Observational Study
Abstract Number: 2083

The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways
Abstract Number: 1020

The Inflammatory and Proliferative Synovial Lesion in Post-Infectious Lyme Arthritis Results from Impaired Wound Healing

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].